Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prenatal intra-amniotic ER004 for male fetuses with XLHED
2024-512632-30-00Phase 2Authorised
- Sponsor
- Pierre Fabre Laboratories
- Start
- Dec 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of EDI200 in ectodermal dysplasia 15 (HED) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Pilocarpine-induced sweat volume at 6 months. Planned start Dec 2021; status: authorised.
02
Drugs
EDI200
03
Conditions
ectodermal dysplasia 15 (HED)
Beyond the preview
Go deeper on 2024-512632-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512632-30-00.